PTEN and prostate cancer: Whilst an early report did not demonstrate a relationship between decreased PTEN expression and sensitivity to PARP inhibition in metastatic prostate cancer cell lines in vitro [327], a more recent study reported that PTEN KD in DU145 cells increases sensitivity to the PARP inhibitor olaparib (AZD2281) when compared with control cells [326].